---
layout: default
title: Silver
parent: 僅模型預測 (L5)
nav_order: 1162
evidence_level: L5
indication_count: 1
---

# Silver
{: .fs-9 }

證據等級: **L5** | 預測適應症: **1** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# SILVER: From Unknown Indication to Bone Paget Disease

## One-Sentence Summary

> SILVER (DrugBank ID: DB12965) has no recorded original indication, no marketed formulation, and no mechanism of action data available. The TxGNN model predicts a possible association with **Bone Paget Disease**, but this prediction appears to stem from a data artifact rather than genuine pharmacological evidence — the supporting "evidence" consists of histological silver-staining technique papers, not treatment studies.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available — no original indications recorded |
| Predicted New Indication | Bone Paget Disease |
| TxGNN Prediction Score | 99.67% |
| Evidence Level | L5 |
| US Market Status | Not marketed (未上市) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for SILVER. No original indications are on record, and the drug has not been approved or marketed in any reviewed jurisdiction, so there is no established clinical use to anchor a mechanistic rationale.

Critically, a review of the underlying literature suggests this prediction is **not mechanistically grounded**. All five literature citations relate to "silver staining" or "silver impregnation" — laboratory histology techniques used to visualize bone tissue sections (e.g., osteoclast nucleolar organizer regions, osteoid quantification) in Paget's disease research. None of these papers describe silver as a therapeutic agent. It is highly likely that the TxGNN knowledge graph conflated the entity "silver" (the drug) with "silver stain" (a laboratory technique term) that co-occurs frequently in Paget's disease pathology literature, producing a high confidence score (99.67%) that does not reflect real pharmacological relevance.

The two clinical trials returned are similarly unrelated: one is a general rare-disease patient registry (not a drug intervention study), and the other concerns phosphate management in end-stage kidney disease with no mention of silver or silver compounds. Neither provides support for a silver–Paget's disease treatment relationship.

---

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT01793168](https://clinicaltrials.gov/study/NCT01793168) | N/A | Recruiting | 20,000 | Rare disease patient registry (CoRDS); not a drug intervention trial, no direct link to silver or Paget's disease treatment |
| [NCT03573089](https://clinicaltrials.gov/study/NCT03573089) | N/A | Recruiting | 3,600 | Phosphate-lowering strategy trial in dialysis patients; no mention of silver or related compounds |

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [9836854](https://pubmed.ncbi.nlm.nih.gov/9836854/) | 1998 | Review/Basic Science | Bone | Silver-stained (AgNOR) nucleolar organizer regions in osteoclast nuclei of Paget's disease — a staining technique, not a treatment study |
| [3163726](https://pubmed.ncbi.nlm.nih.gov/3163726/) | 1988 | Case study | J Nucl Med | Gallium-67 (not silver) citrate localization in Paget's disease osteoclasts |
| [4111887](https://pubmed.ncbi.nlm.nih.gov/4111887/) | 1972 | Histology technique | Stain Technology | Silver staining method for quantifying osteoid in bone sections — methodology paper, not a treatment study |
| [2420233](https://pubmed.ncbi.nlm.nih.gov/2420233/) | 1985 | Histology technique | Anat Anz | Silver impregnation method for bone tissue — methodology paper, not a treatment study |
| [9227338](https://pubmed.ncbi.nlm.nih.gov/9227338/) | 1997 | Basic Science | J Pathol | Vitamin D receptor mRNA quantification technique; no direct relevance to silver |

---

## US Market Information

Currently no marketed authorizations available — SILVER has 0 recorded licenses and a "未上市" (not marketed) status.

---

## Safety Considerations

Please refer to the package insert for safety information. No key warnings, contraindications, or drug interaction data are currently available for SILVER.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN prediction score is high, but the underlying evidence is not credible — the literature base consists entirely of histological "silver staining" technique papers rather than therapeutic studies, and no clinical trials meaningfully support silver as a treatment for Bone Paget Disease. Combined with the absence of original indication, MOA, and market approval data, this candidate does not meet the threshold to proceed.

**To proceed, the following is needed:**
- Resolution of the entity-confusion issue in the knowledge graph (distinguish "silver" the drug from "silver stain" the laboratory technique)
- TFDA label warnings/contraindications (currently blocking — DG001)
- Mechanism of action data from DrugBank or equivalent source (DG002)
- Identification of any genuine original indication(s) for SILVER
- If re-evaluated, a fresh literature search specifically excluding histology/staining-methodology papers
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

